ArticleEJIFCC2021
The use of faecal haemoglobin in deciding which patients presenting to primary care require further investigation (and how quickly) - the FIT approach.
Article in EJIFCC, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Article
- Evaluation of the Sentinel-FOB gold faecal immunochemical test for the presence of haemoglobin using the automated Roche Cobas 8000 system.Practical laboratory medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients presenting to general practitioners (GPs) with new bowel symptoms can be difficult to assess since symptoms are poor predictors of pathology. National Institute for Health and Care Excellence referral guidelines highlight features that may suggest colorectal cancer (CRC) including rectal bleeding, palpable mass, iron deficiency anaemia, but also non-specific symptoms such as weight loss. In those patients referred for investigation on the basis of symptoms alone the yield of CRC is low (2-3%). Faecal immunochemical tests (FIT) quantify faecal haemoglobin (f-Hb) and are widely used in bowel screening programmes. A number of groups have now studied the utility of FIT in patients attending primary care with new bowel symptoms. Studies have concluded that if the FIT is negative and clinical assessment and full blood count normal then the risk of underlying significant bowel disease (SBD) is extremely small. Furthermore, patients with f-Hb ≥400 μgHb/g faeces have >50% risk of SBD and should be investigated urgently. Thus, a single f-Hb requested by GPs provides both a reliable prediction of the absence of SBD, and an objective assessment of the need and urgency of further investigation.
Indexed as
Identifiers
33753974PMC7941063W3137690244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.